Fig. 2: Swimmer plot characterising secondary trial endpoints by the individual patients within each group. | British Journal of Cancer

Fig. 2: Swimmer plot characterising secondary trial endpoints by the individual patients within each group.

From: A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations

Fig. 2: Swimmer plot characterising secondary trial endpoints by the individual patients within each group.The alternative text for this image may have been generated using AI.

 Group 1: BRCA1/2 alterations and Group 2: other homologous recombination repair alterations. TTP1—time to progression prior to trial, with the bar left of 0 depicting duration of therapy and timing of prior therapy in relation to commencing on trial. PID patient ID, CR complete response, PR partial response, SD stable disease, PD progressive disease, EOT end of treatment, TTP2 time to progression on trial.

Back to article page